Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Vaglini

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Oncology Reports|May 20, 2011
TNF-alpha and doxorubicin in hyperthermic perfusion for limb sarcomasC Rossi, M Foletto, A Vecchiato, et al.
Tumori|November 1, 1996
Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalanM Santinami, M Deraco, A Azzarelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593H S Koops, M Vaglini, S Suciu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 5, 1999
Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I studyF Di Filippo, C R Rossi, M Vaglini, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Oncology Reports|May 20, 2011
TNF-alpha and doxorubicin in hyperthermic perfusion for limb sarcomasC Rossi, M Foletto, A Vecchiato, et al.
Tumori|November 1, 1996
Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalanM Santinami, M Deraco, A Azzarelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593H S Koops, M Vaglini, S Suciu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 5, 1999
Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I studyF Di Filippo, C R Rossi, M Vaglini, et al.
Pageof 7